| 1. |
Ferrari S, ?Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, ?2005, 23(34): 8845-8852.
|
| 2. |
Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev, 2012, 12:CD007406.
|
| 3. |
Doval DC, Dutta K, Batra U, et al. Neoadjuvant chemotherapy in breast cancer:review of literature. J Indian Med Assoc, 2013, 111(9):629-631.
|
| 4. |
Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg, 1990, 77(11): 1241-1246.
|
| 5. |
Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intrave-nous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol, 2003, 14(10): 1537-1542.
|
| 6. |
Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park), 2006, 20(10): 1161-1176; discussion 1179-1180, 1185-1166.
|
| 7. |
Antoniou A, Lovegrove RE, Tilney HS, et al. Metaanalysis of clinical outcome after first and second liver resection for colorectal metas-tases. Surgery, 2007, 141(1) : 9-18．.
|
| 8. |
Falcone A, Ricci S, Brunetti I, et al. PhaseⅢtrial of infusional fluo-rouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol, 2007, 25(13): 1670-1676．.
|
| 9. |
Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg, 2003, 7(1) : 109-115; discussion 116-117．.
|
| 10. |
Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg, 2004, 240(6): 1052-1061; discussion 1061-1064．.
|
| 11. |
Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist, 2007, 12(7): 825-839.
|
| 12. |
Wakai T, Shirai Y, Sakata J, et al. Histologic evaluation of intrahe-patic micrometastases in patients treated with or without neoadju-vant chemotherapy for colorectal carcinoma liver metastasis. Int J Clin Exp Pathol, 2012, 5(4): 308-314.
|
| 13. |
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemothe-rapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 2008, 371(9617): 1007-1016.
|
| 14. |
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.
|
| 15. |
Wang ZM, Chen YY, Chen FF, et al. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis. Eur J Surg Oncol, 2015, 41(9): 1197-1203.
|
| 16. |
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemo-therapy as initial treatment for metastatic colorectal cancer. Engl J Med, 2009, 360(14): 1408-1417.
|
| 17. |
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27(5): 663-671.
|
| 18. |
Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol, 2014, 15(6): 601-611.
|
| 19. |
Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capeci-tabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol, 2008, 26(11): 1830-1835.
|
| 20. |
Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant FOLFIRI+bevaciz-umab in patients with resectable liver metas tases from colorectal cancer: a phase 2 trial. Br J Cancer, 2013, 108(8): 1566-1570.
|
| 21. |
D'Angelica MI, Correa-Gallego C, Paty PB, et al. PhaseⅡtrial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conver-sion to resection and long-term outcomes. Ann Surg, 2015, 261(2): 353-360.
|
| 22. |
Chan DL, Alzahrane NA, Morris DL, et al. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol, 2015, 24(3): 162-171.
|
| 23. |
Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg, 2013, 148(12): 1103-1108.
|
| 24. |
Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg, 2007, 11(7): 860-868.
|
| 25. |
Lehmann K, Rickenbacher A, Weber A, et al. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg, 2012, 255(2) : 237-247．.
|
| 26. |
Zdenkowski N, Chen S, van der Westhuizen A, et al. Curative strate-gies for liver metastases from colorectal cancer: a review．Oncologist, 2012, 17(2) : 201-211．.
|
1/5
WeChat